Despite the number of drugs currently in the pipeline for the treatment of systemic lupus erythematosus (SLE), the panelists raise concerns about unaddressed factors that may continue to impede a clinician’s decision to recommend a treatment option to a patient.
Michelle Petri, MD, MPH, explains that newly-approved therapy options still lack personalized biomarkers and do not provide important long-term outcomes data that help professionals make decisions about treatment for patients with SLE.
Patrick F. Fogarty, MD, further explains that when defining the value of medical therapy, an economic consideration continues to stand in the way of treatment recommendations.
Without addressing these issues, Dr Petri and Dr Fogarty agree that when selecting appropriate therapy for a patient, and when considering the costs associated with a treatment option, it is important to individualize therapy for patients with SLE.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen